Colchicine Intoxication Subsequent to an Autolytic Attempt with Positive Evolution

Beatriz Nieto Martino, Walter Andrés Ramírez Lajones, Ángela Alonso Ovies
{"title":"Colchicine Intoxication Subsequent to an Autolytic Attempt with Positive Evolution","authors":"Beatriz Nieto Martino, Walter Andrés Ramírez Lajones, Ángela Alonso Ovies","doi":"10.33696/casereports.5.028","DOIUrl":null,"url":null,"abstract":"Background and objectives: Colchicine is a drug that has been used to treat gout for several centuries, it is also indicated in certain autoimmune diseases and has been tested as a chemotherapeutic. Only a few cases of intoxication by this drug have been described, but it is known that it has a narrow therapeutic margin (0.5 to 0.8 mg/kg), almost always resulting in fatal results above these limits. Regarding therapeutic management, the initiation of supportive measures is essential. Initial strategies are gastric lavage, administration of activated charcoal and fluid resuscitation aimed at preventing renal failure. Case report: A 63-year-old man with a history of spondylodiscitis and gouty arthropathy, receiving colchicine treatment. He reported abdominal symptoms with nausea, vomiting, watery stools, and diffuse pain after taking 36 tablets of 1 mg of colchicine due to exacerbation of arthralgias (the patient later recognized the autolytic ideation). He was hospitalized in the ICU due to hemodynamic instability, severe pancytopenia, respiratory failure requiring mechanical ventilation and non-oliguric acute renal failure. The patient improved and was discharged from the ICU after 14 days. Conclusions: Colchicine poisoning is rare and has high mortality despite the favorable evolution of our patient. There is no specific treatment at the moment and management should emphasize early admission to the ICU, close monitoring and organ support measures.","PeriodicalId":93075,"journal":{"name":"Archives of medical case reports","volume":"99 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of medical case reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33696/casereports.5.028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objectives: Colchicine is a drug that has been used to treat gout for several centuries, it is also indicated in certain autoimmune diseases and has been tested as a chemotherapeutic. Only a few cases of intoxication by this drug have been described, but it is known that it has a narrow therapeutic margin (0.5 to 0.8 mg/kg), almost always resulting in fatal results above these limits. Regarding therapeutic management, the initiation of supportive measures is essential. Initial strategies are gastric lavage, administration of activated charcoal and fluid resuscitation aimed at preventing renal failure. Case report: A 63-year-old man with a history of spondylodiscitis and gouty arthropathy, receiving colchicine treatment. He reported abdominal symptoms with nausea, vomiting, watery stools, and diffuse pain after taking 36 tablets of 1 mg of colchicine due to exacerbation of arthralgias (the patient later recognized the autolytic ideation). He was hospitalized in the ICU due to hemodynamic instability, severe pancytopenia, respiratory failure requiring mechanical ventilation and non-oliguric acute renal failure. The patient improved and was discharged from the ICU after 14 days. Conclusions: Colchicine poisoning is rare and has high mortality despite the favorable evolution of our patient. There is no specific treatment at the moment and management should emphasize early admission to the ICU, close monitoring and organ support measures.
秋水仙碱中毒后的自溶尝试与阳性进化
背景和目的:秋水仙碱是一种用于治疗痛风几个世纪的药物,它也适用于某些自身免疫性疾病,并已被测试作为一种化疗药物。据报道,这种药物中毒的病例很少,但众所周知,它的治疗范围很窄(0.5至0.8毫克/公斤),几乎总是导致超过这些限度的致命结果。关于治疗管理,支持性措施的启动是必不可少的。最初的策略是洗胃,给药活性炭和液体复苏旨在防止肾功能衰竭。病例报告:63岁男性,有脊柱椎间盘炎和痛风性关节病病史,接受秋水仙碱治疗。患者因关节痛加重,服用秋水仙碱1 mg 36片后出现恶心、呕吐、水样便、弥漫性疼痛等腹部症状(患者后来认识到自溶意识)。患者因血流动力学不稳定、严重全血细胞减少、需要机械通气的呼吸衰竭和非少尿性急性肾功能衰竭而住进ICU。患者病情好转,14天后出院。结论:秋水仙碱中毒是罕见的,尽管我们的病人进化良好,但死亡率很高。目前尚无具体的治疗方法,管理应强调尽早入院,密切监测和器官支持措施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信